The parntership allows PRECOS to validate RCT’s existing research using its validated patient relevant cancer models like in vitro 2D and 3D assays, in vivo therapeutic evaluations and post-study analyses.
Preclinical Oncology Services chairman Neil Rotherham said their advanced models challenge new therapeutic agents similar to the situation in the patient thereby providing clinically predictive data which they have applied to a broad spectrum of therapies including complementary therapies.